Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia

Patient Preference and Adherence

Volumn 1, Issue , 2007, Pages 9-17

  Liu Seifert, Hong ^a   Adams, David H ^a   Ascher Svanum, Haya ^a   Faries, Douglas E ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adherence; Antipsychotic; Compliance; Patient attitude; Schizophrenia

Indexed keywords

EID: 77956279365     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S     Document Type: Article

References (29)

1. Ayuso-Gutierrez JL, del Rio Vega JM. 1997. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res, 28:199-206.
2. Becker M. H, Maiman LA. 1975. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care, 13:10-24.
3. Coldham E. L, Addington J, Addington D. 2002. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand, 106:286-90.
4. Davis J. M, Chen N. 2001. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry, 62:757-71.
5. de Millas W, Lambert M, Naber D. 2006. The impact of subjective wellbeing under neuroleptic treatment on compliance and remission. Dialogues Clin Neurosci, 8:131-6.
6. Elboqen E. B, Swanson JW, Swartz MS, et al. 2005. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis, 193:673-9.
7. Fenton W. S, Blyler CR, Heinssen RK. 1997. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull, 23:637-51.
8. Freudenreich O., Cather C, Evins AE, et al. 2004. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry, 65:1372-6.
9. Kamali M., Kelly BD, Clarke M, et al. 2006. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry, 21:29-33.
10. Kampman O., Lehtinen K. 1999. Compliance in psychoses. Acta Psychiatr Scand, 100:167-75.
11. Karow A., Czekall J, Dittmann RW, et al. 2007. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry, 68:75-80.
12. Kay S. R, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull, 13:261-76.
13. Kikkert M. J, Schene AH, Koeter MW, et al. 2006. Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophr Bull, 32:786-94.
14. Lehman A.F. 1988. A quality of life interview for the chronically mentally ill. Eval Program Plann, 11:51-62.
15. Lieberman J. A, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353:1209-23.
16. Liu-Seifert H, Adams DH, Kinon BJ. 2005. Discontinuation of treatment of schizophrenic patients was driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med, 3:21.
17. Liu-Seifert H, Houston JP, Adams DH, et al. 2007. Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia. J Clin Psychopharmacol, 27:392-4.
18. Loffler W, Kilian R, Toumi M, et al. 2003. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry, 36:105-12.
19. Marder S. R, Mebane A, Chien CP, et al. 1983. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry, 140:470-2.
20. McEvoy JP, Lieberman JA, Stroup TS, et al. 2006. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163:600-10.
21. Perkins D.O. 1999. Adherence to antipsychotic medications. J Clin Psychiatry, 60:25-30.
22. Perkins D.O. 2002. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry, 63:1121-8.
23. Perkins D. O, Johnson JL, Hamer RM, et al. 2006. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res, 83:53-63.
24. Puschner B., Born A, Giessler A, et al. 2006. Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study. J Nerv Ment Dis, 194:746-752.
25. Stroup T. S, Lieberman JA, McEvoy JP, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 163:611-22.
26. Stroup T. S, Lieberman JA, McEvoy JP, et al. 2007. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry, 164:415-27.
27. Tunis S. L, Faries DE, Nyhuis AW, et al. 2006. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health, 9:77-89.
28. Valenstein M., Copeland LA, Blow FC, et al. 2002. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care, 40:630-9.
29. Weiden P., Rapkin B, Mott T, et al. 1994. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull, 20:297-310.